# Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors

> **NCT07726446** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** PD-1 and chemotherapy
- **PROCEDURE:** cryoablation

## Key facts

- **NCT ID:** NCT07726446
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-10
- **Final completion:** 2030-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726446, "Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07726446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*